Xin Lang Cai Jing·2025-09-16 03:38Core Viewpoint - Tiger Med's stock price has experienced fluctuations, with a year-to-date increase of 11.41% but a recent decline of 6.40% over the past five trading days [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - As of June 30, 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed in the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.14% to 51,500 [2] - The top circulating shareholders include China Europe Medical Health Mixed A, holding 27.634 million shares, and Hong Kong Central Clearing Limited, holding 23.266 million shares, with respective changes in holdings noted [3]